Important Regulatory Milestone Provides Runway to Move DK210 (EGFR) into the Clinical Phase
GERMANTOWN, Md., Dec. 27, 2022 /PRNewswire/ — Today, Deka Biosciences, Inc. (Deka), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on December 23, 2022. The IND application supports Deka’s DK210 (EGFR), a promising new cancer treatment that combines normal interleukin-2 with a high affinity interleukin-10, that is designed to accumulate in tumors by binding to the epidermal growth factor receptor (EGFR).
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.